p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form
Journal of Cell Science · 2023
DOI: 10.1242/jcs.261017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2023. Verfasst von Shinjinee Sengupta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India. Hauptthemen laut MEDLINE: Stomach Neoplasms, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: DBT-Wellcome Trust India Alliance, Department of Biotechnology, Ministry of Science and Technology, India, Wadhwani Research Center for Bioengineering.
Abstract (Originalsprache)
p53 (also known as TP53) mutation and amyloid formation are long associated with cancer pathogenesis; however, the direct demonstration of the link between p53 amyloid load and cancer progression is lacking. Using multi-disciplinary techniques and 59 tissues (53 oral and stomach cancer tumor tissue samples from Indian individuals with cancer and six non-cancer oral and stomach tissue samples), we showed that p53 amyloid load and cancer grades are highly correlated. Furthermore, next-generation sequencing (NGS) data suggest that not only mutant p53 (e.g. single-nucleotide variants, deletions, and insertions) but wild-type p53 also formed amyloids either in the nucleus (50%) and/or in the cytoplasm in most cancer tissues. Interestingly, in all these cancer tissues, p53 displays a loss of DNA-binding and transcriptional activities, suggesting that the level of amyloid load correlates with the degree of loss and an increase in cancer grades. The p53 amyloids also sequester higher amounts of the related p63 and p73 (also known as TP63 and TP73, respectively) protein in higher-grade tumor tissues. The data suggest p53 misfolding and/or aggregation, and subsequent amyloid formation, lead to loss of the tumor-suppressive function and the gain of oncogenic function, aggravation of which might determine the cancer grade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Noida, Uttar Pradesh, 201303, India.
- Centre for BioSystems Science and Engineering, Indian Institute of Science Bengaluru, Bengaluru, Karnataka 560012, India.
ORCID-Profile: Shinjinee Sengupta, Ajoy Paul, Debalina Datta, Debdeep Chatterjee, Laxmikant Gadhe, Mohit Kumar Jolly, Samir K Maji
Förderung
- DBT-Wellcome Trust India Alliance
- Department of Biotechnology, Ministry of Science and Technology, India
- Wadhwani Research Center for Bioengineering
- Department of Science and Technology, Ministry of Science and Technology
- The Wellcome Trust DBT India Alliance
- Council of Scientific and Industrial Research
Zitieren
APA
Sengupta, S., Singh, N., Paul, A., Datta, D., Chatterjee, D., Mukherjee, S., Gadhe, L., Devi, J., Mahesh, Y., Jolly, M. K., & Maji, S. K. (2023). p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form. Journal of Cell Science. https://doi.org/10.1242/jcs.261017
Vancouver
Sengupta S, Singh N, Paul A, Datta D, Chatterjee D, Mukherjee S, et al. p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form. Journal of Cell Science. 2023. doi:10.1242/jcs.261017
BibTeX
@article{Sengupta2023,
author = {Sengupta, Shinjinee and Singh, Namrata and Paul, Ajoy and Datta, Debalina and Chatterjee, Debdeep and Mukherjee, Semanti and Gadhe, Laxmikant and Devi, Jyoti and Mahesh, Yeshwanth and Jolly, Mohit Kumar and Maji, Samir K},
title = {p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form},
journal = {Journal of Cell Science},
year = {2023},
doi = {10.1242/jcs.261017}
}
EUVIMED